{
  "id": 20296281,
  "title": "Jefferies reiterates Buy on AbCellera stock, $21 target on VMS therapy",
  "url": "https://urgent.news/2026/11/16/jefferies-reiterates-buy-on-abcellera-stock-21-target-on-vms-therapy",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T16:25:00.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jefferies-reiterates-buy-on-abcellera-stock-21-target-on-vms-therapy-93CH-5030524"
  },
  "original_language": "en",
  "account": "Jefferies has reaffirmed its Buy rating for AbCellera Biologics (NASDAQ:ABCL) stock, maintaining a $21.00 price target. The company's stock is currently trading at $11.40, far below the analyst's target range of $14 to $30. Despite this, AbCellera has delivered an impressive 236% return year-to-date.\n\nWhile the company is seen as potentially overvalued at its current valuation, three analysts have recently revised their earnings estimates upward. Jefferies highlights ABCL635 as a nonhormonal VMS therapy with strong potential for pivotal development and franchise value creation. For upcoming data, efficacy is expected to be assessed through the week 12 single-dose washout, which will inform dose selection rather than testing sustained benefit.\n\nThe positive outlook includes an encouraging execution framework with an existing formulation supporting one monthly injection. Other commercial opportunities include telehealth, direct-to-consumer sales, oncology-associated VMS, and quarterly payments. In its latest financial report, AbCellera showed a revenue increase to $10.6 million, surpassing Wall Street's forecast of $6.21 million, marking a 71.18% beat. The company also reported a narrower net loss of $41.0 million, or $0.13 per share, compared to the expected $0.17 loss.\n\nStoneX raised its price target for AbCellera to $15 from $11, maintaining a Buy rating. Meanwhile, AbCellera's lead antibody program, ABCL635, has shown promising late-stage-ready data. The company plans to begin late-stage development of ABCL635 in 2027. With cash and marketable securities exceeding $790 million and total available liquidity over $890 million, AbCellera is making significant strides in clinical development.",
  "summary": null,
  "key_points": [
    "Jefferies maintains Buy rating on AbCellera stock with $21 target",
    "AbCellera's ABCL635 shows promising late-stage-ready data",
    "Company reports 71.18% revenue beat and narrower net loss"
  ],
  "editors_take": "The upward revision of earnings estimates and strong revenue beats signal that AbCellera is successfully transitioning from a research-focused entity toward a commercially viable developer of high-value VMS therapies.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}